Nifty
:
9039.25
Sensex
:
30672.59
-67.00 (-0.74%)
-260.31 (-0.84%)
Nifty
Sensex
:
:
9039.25
30672.59
-67.00 (-0.74%)
-260.31 (-0.84%)

Cipla Ltd.

Pharmaceuticals & Drugs - Global

Rating :
71/99

BSE: 500087 | NSE: CIPLA

NSE BSE
639.35
22-May-2020
  • Open
  • High
  • Low
  • Previous Close
  •  616.70
  •  641.85
  •  610.10
  •  616.60
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  10875625
  •  68287.16
  •  641.85
  •  355.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 51,518.69
  • 33.31
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 55,216.11
  • 0.47%
  • 3.27

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 36.68%
  • 4.18%
  • 15.92%
  • FII
  • DII
  • Others
  • 17.98%
  • 22.20%
  • 3.04%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.81
  • 7.60
  • 4.36

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.33
  • 5.82
  • 2.99

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.62
  • 5.08
  • 15.09

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 30.28
  • 33.95
  • 32.70

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.55
  • 3.43
  • 3.07

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.76
  • 16.60
  • 14.62

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Net Sales
4,376.19
4,403.98
-0.63%
4,371.00
4,007.54
9.07%
4,395.78
4,011.90
9.57%
3,989.02
3,938.99
1.27%
Expenses
3,742.67
3,442.93
8.71%
3,612.67
3,299.87
9.48%
3,486.28
3,309.68
5.34%
3,084.38
3,212.62
-3.99%
EBITDA
633.52
961.05
-34.08%
758.33
707.67
7.16%
909.50
702.22
29.52%
904.64
726.37
24.54%
EBIDTM
14.48%
21.82%
17.35%
17.66%
20.69%
17.50%
22.68%
18.44%
Other Income
93.18
95.36
-2.29%
72.13
78.53
-8.15%
100.52
132.57
-24.18%
78.37
170.11
-53.93%
Interest
53.00
44.78
18.36%
46.17
44.19
4.48%
46.07
44.37
3.83%
52.12
35.09
48.53%
Depreciation
345.80
510.28
-32.23%
277.89
293.13
-5.20%
282.96
281.90
0.38%
268.00
241.00
11.20%
PBT
327.90
501.35
-34.60%
506.40
448.88
12.81%
680.99
508.52
33.92%
662.89
620.39
6.85%
Tax
85.59
127.75
-33.00%
152.82
125.68
21.59%
200.55
142.39
40.85%
192.24
173.71
10.67%
PAT
242.31
373.60
-35.14%
353.58
323.20
9.40%
480.44
366.13
31.22%
470.65
446.68
5.37%
PATM
5.54%
8.48%
8.09%
8.06%
10.93%
9.13%
11.80%
11.34%
EPS
3.05
4.56
-33.11%
4.35
4.12
5.58%
5.85
4.68
25.00%
5.93
5.60
5.89%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
17,131.99
16,362.41
15,155.71
14,394.29
13,594.89
11,345.44
10,173.39
8,279.33
7,020.71
6,323.84
5,359.52
Net Sales Growth
4.70%
7.96%
5.29%
5.88%
19.83%
11.52%
22.88%
17.93%
11.02%
17.99%
 
Cost Of Goods Sold
5,991.42
5,784.49
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
2,952.61
2,739.30
2,775.18
2,452.98
Gross Profit
11,140.57
10,577.92
9,717.29
9,077.17
8,505.03
7,074.81
6,298.56
5,326.72
4,281.41
3,548.66
2,906.54
GP Margin
65.03%
64.65%
64.12%
63.06%
62.56%
62.36%
61.91%
64.34%
60.98%
56.12%
54.23%
Total Expenditure
13,926.00
13,494.26
12,702.32
11,918.50
11,115.22
9,183.74
8,040.34
6,081.48
5,361.86
4,954.60
4,286.56
Power & Fuel Cost
-
335.11
298.82
251.73
245.92
228.28
218.63
233.12
235.35
198.55
92.15
% Of Sales
-
2.05%
1.97%
1.75%
1.81%
2.01%
2.15%
2.82%
3.35%
3.14%
1.72%
Employee Cost
-
2,856.53
2,690.10
2,633.82
2,434.01
1,967.72
1,542.96
1,036.02
772.50
565.59
289.59
% Of Sales
-
17.46%
17.75%
18.30%
17.90%
17.34%
15.17%
12.51%
11.00%
8.94%
5.40%
Manufacturing Exp.
-
1,284.94
1,220.67
1,192.77
1,596.79
737.11
644.42
541.58
583.18
627.94
708.39
% Of Sales
-
7.85%
8.05%
8.29%
11.75%
6.50%
6.33%
6.54%
8.31%
9.93%
13.22%
General & Admin Exp.
-
1,096.50
1,002.43
868.31
845.89
743.46
638.08
496.81
369.85
288.71
231.05
% Of Sales
-
6.70%
6.61%
6.03%
6.22%
6.55%
6.27%
6.00%
5.27%
4.57%
4.31%
Selling & Distn. Exp.
-
1,281.29
1,082.90
1,009.21
818.76
738.87
680.32
466.22
467.61
386.67
326.48
% Of Sales
-
7.83%
7.15%
7.01%
6.02%
6.51%
6.69%
5.63%
6.66%
6.11%
6.09%
Miscellaneous Exp.
-
855.40
968.98
645.54
83.99
497.67
441.10
355.12
194.07
111.96
326.48
% Of Sales
-
5.23%
6.39%
4.48%
0.62%
4.39%
4.34%
4.29%
2.76%
1.77%
3.47%
EBITDA
3,205.99
2,868.15
2,453.39
2,475.79
2,479.67
2,161.70
2,133.05
2,197.85
1,658.85
1,369.24
1,072.96
EBITDA Margin
18.71%
17.53%
16.19%
17.20%
18.24%
19.05%
20.97%
26.55%
23.63%
21.65%
20.02%
Other Income
344.20
476.57
357.65
228.69
208.21
165.55
265.37
222.14
139.52
91.68
353.50
Interest
197.36
168.43
114.23
159.38
206.63
168.29
145.74
33.91
38.34
25.10
28.30
Depreciation
1,174.65
1,097.15
949.83
1,322.93
754.22
504.71
372.64
330.48
312.22
273.33
167.07
PBT
2,178.18
2,079.14
1,746.98
1,222.17
1,727.03
1,654.25
1,880.04
2,055.60
1,447.81
1,162.49
1,231.09
Tax
631.20
569.53
250.11
179.76
331.59
400.03
463.38
544.31
306.51
195.22
243.50
Tax Rate
28.98%
27.39%
14.98%
14.71%
19.20%
24.18%
24.65%
25.98%
21.17%
16.79%
18.36%
PAT
1,546.98
1,544.87
1,413.31
1,013.38
1,372.01
1,206.07
1,400.73
1,551.06
1,141.30
967.27
1,082.59
PAT before Minority Interest
1,593.98
1,509.61
1,419.35
1,042.41
1,395.44
1,254.22
1,416.66
1,551.06
1,141.30
967.27
1,082.59
Minority Interest
47.00
35.26
-6.04
-29.03
-23.43
-48.15
-15.93
0.00
0.00
0.00
0.00
PAT Margin
9.03%
9.44%
9.33%
7.04%
10.09%
10.63%
13.77%
18.73%
16.26%
15.30%
20.20%
PAT Growth
2.48%
9.31%
39.46%
-26.14%
13.76%
-13.90%
-9.69%
35.90%
17.99%
-10.65%
 
Unadjusted EPS
19.18
18.97
17.53
12.52
16.93
14.71
17.29
19.24
14.25
12.32
13.70

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
15,012.28
14,229.19
12,543.66
11,516.22
10,801.49
10,050.35
9,018.68
7,638.93
6,666.13
5,910.57
Share Capital
161.14
161.02
160.90
160.68
160.59
160.58
160.58
160.58
160.58
160.58
Total Reserves
14,794.10
14,001.91
12,320.74
11,266.12
10,557.74
9,868.12
8,858.10
7,478.35
6,505.55
5,749.99
Non-Current Liabilities
4,646.15
4,259.05
4,514.99
1,407.13
2,417.66
2,028.05
1,024.96
824.27
697.34
184.22
Secured Loans
47.70
0.00
0.00
207.00
287.09
317.44
0.00
0.00
15.00
0.41
Unsecured Loans
3,782.37
3,662.11
3,645.36
14.88
22.19
0.43
0.55
3.25
2.92
4.66
Long Term Provisions
121.41
137.92
140.52
144.68
1,783.17
1,368.64
713.87
557.78
466.30
0.00
Current Liabilities
3,771.51
3,832.22
3,388.91
7,776.05
3,881.13
2,563.58
2,277.63
1,413.19
1,698.54
2,525.63
Trade Payables
1,947.99
2,119.12
1,586.30
1,475.82
1,452.06
979.53
828.36
691.77
720.88
805.41
Other Current Liabilities
541.86
647.04
908.95
1,006.14
654.55
408.67
250.89
489.93
235.28
192.56
Short Term Borrowings
486.16
435.87
467.23
4,969.67
1,392.48
910.47
966.38
10.20
523.06
0.00
Short Term Provisions
795.50
630.19
426.43
324.42
382.04
264.91
232.00
221.29
219.32
1,527.66
Total Liabilities
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42
Net Block
9,546.51
9,949.14
9,508.16
9,368.32
6,829.64
6,496.47
3,609.97
3,215.49
3,094.18
2,011.17
Gross Block
13,665.08
12,960.01
11,370.70
10,167.62
9,561.55
8,676.27
5,317.52
4,626.35
4,240.55
2,897.26
Accumulated Depreciation
4,108.55
3,010.87
1,609.71
799.30
2,731.91
2,179.80
1,707.55
1,410.86
1,146.37
886.09
Non Current Assets
11,335.28
11,858.80
12,082.23
12,208.26
9,689.47
9,039.59
5,537.29
4,819.58
4,618.88
2,696.41
Capital Work in Progress
676.18
981.33
1,682.98
2,060.87
580.90
441.84
377.79
371.17
285.34
684.24
Non Current Investment
490.20
157.66
137.36
176.35
249.76
397.14
415.69
328.59
367.18
1.00
Long Term Loans & Adv.
455.57
514.96
543.67
426.18
1,860.78
1,552.40
978.96
865.38
841.20
0.00
Other Non Current Assets
166.82
255.71
210.06
176.54
168.39
151.74
154.88
38.95
30.98
0.00
Current Assets
12,426.63
10,814.10
8,803.56
8,841.23
7,591.29
5,651.97
6,783.98
5,056.81
4,443.13
5,924.01
Current Investments
2,125.79
1,102.21
837.39
582.34
390.02
311.43
2,116.75
940.52
223.59
245.41
Inventories
3,964.83
4,044.70
3,519.72
3,808.05
3,780.62
2,895.26
2,387.07
1,850.08
1,906.16
1,512.58
Sundry Debtors
4,150.72
3,102.45
2,582.17
2,356.27
1,997.72
1,638.89
1,668.84
1,553.58
1,490.82
1,566.63
Cash & Bank
618.81
965.61
638.27
871.40
564.26
175.76
143.01
90.46
95.97
62.06
Other Current Assets
1,566.48
480.20
418.17
437.05
858.67
630.63
468.31
622.17
726.59
2,537.33
Short Term Loans & Adv.
1,150.49
1,118.93
807.84
786.12
713.07
595.13
463.21
459.94
533.77
2,387.57
Net Current Assets
8,655.12
6,981.88
5,414.65
1,065.18
3,710.16
3,088.39
4,506.35
3,643.62
2,744.59
3,398.38
Total Assets
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,691.14
1,462.76
2,381.76
1,740.81
1,173.43
1,563.31
1,397.67
1,712.76
1,025.10
1,043.03
PBT
2,079.14
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
2,095.38
1,447.81
1,162.49
1,326.09
Adjustment
1,268.77
1,293.82
1,374.42
950.85
630.05
552.80
283.82
396.66
288.84
146.53
Changes in Working Capital
-1,063.54
-778.48
235.44
-429.38
-718.61
-561.26
-519.84
199.76
-162.03
-173.82
Cash after chg. in Working capital
2,284.37
2,184.80
2,832.03
2,248.50
1,565.69
1,871.58
1,859.36
2,044.23
1,289.30
1,298.80
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-593.23
-722.04
-450.27
-507.69
-392.26
-308.27
-461.69
-331.47
-264.20
-255.77
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,668.68
-854.01
-1,310.21
-4,522.63
-941.15
-1,249.86
-2,062.89
-965.10
-908.39
-562.75
Net Fixed Assets
-173.15
-509.84
-889.04
1,487.25
-534.38
-437.26
-692.52
-460.09
-601.86
-520.07
Net Investments
-1,239.74
-351.09
-30.10
164.99
-833.97
-985.31
-1,566.67
-464.50
-305.55
-183.78
Others
-255.79
6.92
-391.07
-6,174.87
427.20
172.71
196.30
-40.51
-0.98
141.10
Cash from Financing Activity
-348.72
-385.48
-1,325.68
3,104.06
164.78
-265.63
717.77
-753.17
-82.80
-471.61
Net Cash Inflow / Outflow
-326.26
223.27
-254.13
322.24
397.06
47.82
52.55
-5.51
33.91
8.67
Opening Cash & Equivalents
853.47
610.35
858.15
545.84
175.76
143.01
90.46
95.97
62.06
53.39
Closing Cash & Equivalent
508.36
853.46
610.35
858.15
564.26
175.76
143.01
90.46
95.97
62.06

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
185.62
175.92
155.15
142.23
133.38
124.79
112.21
95.03
82.91
73.50
ROA
6.50%
6.52%
4.97%
7.28%
7.85%
10.49%
13.97%
12.05%
10.94%
13.38%
ROE
10.37%
10.65%
8.72%
12.61%
12.10%
14.89%
18.64%
15.98%
15.40%
21.14%
ROCE
11.94%
10.20%
8.28%
13.24%
15.33%
19.05%
24.15%
19.96%
18.08%
24.22%
Fixed Asset Turnover
1.80
1.25
1.36
1.40
1.26
1.47
1.69
1.61
1.79
1.94
Receivable days
55.36
68.17
61.60
57.62
57.94
58.66
70.11
77.94
87.29
115.32
Inventory Days
61.13
90.71
91.41
100.43
106.36
93.68
92.19
96.16
97.61
98.17
Payable days
59.02
57.37
46.96
48.81
52.17
44.93
48.58
50.51
56.11
69.48
Cash Conversion Cycle
57.47
101.50
106.05
109.24
112.14
107.41
113.72
123.59
128.78
144.01
Total Debt/Equity
0.29
0.29
0.33
0.46
0.16
0.12
0.11
0.00
0.09
0.00
Interest Cover
13.34
15.61
8.67
9.36
10.83
13.90
62.79
38.76
47.31
47.86

Annual Reports:

FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011
FY 2010

News Update:


  • Cipla gets USFDA’s final approval for Dihydroergotamine Mesylate Nasal Spray
    21st May 2020, 09:06 AM

    The company is the first approved applicant for such CGT and, is therefore, eligible for 180 days of CGT exclusivity which will begin to run from the commercial marketing of Cipla’s product

    Read More
  • Cipla files ANDA for generic version of GSK’s Advair Diskus
    18th May 2020, 10:06 AM

    The company had recently announced the successful completion of its Phase-3 clinical end-point study for the product in the first attempt

    Read More
  • Cipla reports fall of 33% in Q4 consolidated net profit
    16th May 2020, 15:35 PM

    Total income of the company decreased by 0.67% at Rs 4469.37 crore for Q4FY20

    Read More
  • Cipla inks pact with with Gilead Sciences
    13th May 2020, 09:26 AM

    This agreement is part of company’s efforts to enhance global access to lifesaving treatments for patients affected by the pandemic

    Read More
  • Cipla gets EIR from USFDA for API manufacturing facility in Bangalore
    9th May 2020, 09:21 AM

    The agency had conducted inspection from January 20, 2020 to January 24, 2020

    Read More
  • Cipla stands strong with India in battle against COVID-19
    21st Apr 2020, 14:59 PM

    The company has set up Rs 25 crore ‘Caring for Life’ COVID-19 dedicated Fund to support the Indian Government

    Read More
  • Cipla gets final approval for Albuterol Sulfate Inhalation Aerosol
    9th Apr 2020, 11:22 AM

    It is used for treatment of acute episodes of bronchospasm or prevention of asthmatic symptoms

    Read More
  • Cipla completes Phase-3 clinical study for generic version of GSK's Advair Diskus
    2nd Apr 2020, 15:21 PM

    The Phase-3 study, successfully completed in the first attempt, was conducted over a period of 15 months at over 100 sites in the US

    Read More
  • Cipla gets USFDA's nod for Esomeprazole for oral suspension
    26th Mar 2020, 12:20 PM

    Esomeprazole for Oral Suspension 10mg, 20mg and 40mg is AB-rated generic therapeutic equivalent version of AstraZeneca Pharmaceutical’s Nexium

    Read More
  • Cipla collaborates with CSIR-IICT
    18th Mar 2020, 10:36 AM

    The partnership is to work on development of anti- viral drugs to contain COVID-19

    Read More
  • Cipla receives warning letter from USFDA for Goa manufacturing facility
    26th Feb 2020, 09:46 AM

    The USFDA had conducted inspection from September 16, 2019 to September 27, 2019

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.